No association between polymorphisms of WNT2 and schizophrenia in a Korean population by Kim, Hak-Jae et al.
Kim et al. BMC Medical Genetics 2010, 11:78
http://www.biomedcentral.com/1471-2350/11/78
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Kim et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article No association between polymorphisms of WNT2 
and schizophrenia in a Korean population
Hak-Jae Kim1, Jin Kyung Park2, Su Kang Kim3, Sung Wook Kang3, Jong Woo Kim2, Hyun-Kyung Park4, Ah-Rang Cho2, 
Ji Young Song2 and Joo-Ho Chung*3
Abstract
Background: Wingless-type MMTV integration site family member 2 (WNT2) has a potentially important role in 
neuronal development; however, there has yet to be an investigation into the association between single nucleotide 
polymorphisms (SNPs) of WNT2 and schizophrenia. This study aimed to determine whether certain SNPs of WNT2 were 
associated with schizophrenia in a Korean population.
Methods: e genotyped 7 selected SNPs in the WNT2 gene region (approximately 46 Kb) using direct sequencing in 288 
patients with schizophrenia and 305 healthy controls.
Results: Of the SNPs examined, one SNP showed a weak association with schizophrenia (p = 0.017 in the recessive 
model). However, this association did not remain statistically significant after Bonferroni correction.
Conclusion: The present study does not support a major role for WNT2 in schizophrenia. This could be due to the size 
of the population. Therefore, additional studies would be needed to definitively rule out the gene's minor effects.
Background
Schizophrenia is a complex disease that develops in
approximately 0.5-1.0% of the global population and
inflicts physical suffering and mental anguish on the
affected individuals and their families [1,2]. The neurode-
velopmental theory of schizophrenia postulates that
abnormal neurodevelopment is one of the etiological fac-
tors of schizophrenia [3-6]. Recent studies suggest that
schizophrenia may be a subtle disorder of brain develop-
ment or plasticity [7-9].
Wnt proteins belong to a family of molecules that
locally activate cell signaling pathways, regulating cell fate
and playing an important role in development [10]. Evi-
dence suggests that Wnt signaling and insulin signaling,
which regulates glycogen synthase kinase-3 (GSK-3), may
be important in schizophrenia [11]. Several lines of evi-
dence support the association between signaling aberra-
tions and schizophrenia. However, research has shown
changes in gene expressions in schizophrenia [12-16],
and, in particular, that some such changes affect GSK-3
[14,17-19]. Researchers have also found Wnt signaling
abnormalities associated with schizophrenia. For exam-
ple, expressions of β-catenin proteins decreased in the
brains of schizophrenia patients, presumably due to aber-
rant regulation of β-catenin degradation mediated by
activated GSK-3β [20,21]. Another report suggested the
enhanced GSK-3β activity was secondary to diminished
phosphorylation by Akt, since there is decreased Akt
expression in schizophrenia patients' brains [22]. Further-
more, researchers found increased Wnt-1 expression in
the hippocampi of schizophrenia patients relative to nor-
mal subjects. Wnt-1 is an important molecule in the Wnt
pathway [23]. Several studies have implicated Wnt signal-
ing genes in bipolar disorder, as well as in schizophrenia.
Researcher found that the frizzled-3 gene (FZD3), which
encodes a receptor for Wnt ligands, was associated with
schizophrenia in 3 different samples [24-26].
The wingless-type MMTV integration site family,
member 2 (WNT2) gene is located at chromosome
7q31.2, a region that, in a genome scan study, showed evi-
dence of a link to schizophrenia [27]. WNT2 is one of the
WNT genes that are expressed in a variety of tissues dur-
ing development [28]. Knockout and expression studies
in mice, zebra fish, and Xenopus  have demonstrated
WNT genes' crucial roles in the development and pat-
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terning of the central nervous system [29-31]. WNT
genes encode several signaling proteins that are essential
in embryo patterning, cell proliferation, and cell determi-
nation [32,33]. The WNT signaling pathway also includes
several receptors expressed in both developing and
mature nervous systems [34].
Previously, several studies have addressed whether the
WNT2 gene is associated with autism, a neurodevelop-
mental disorder [35-37]. Although Wassink et al.
reported that one of WNT2 SNPs (rs2024233 on exon 5)
is associated with autism [35], following association stud-
ies did not find any significant associations with autism
[36,37]. In addition, Proitsi et al. performed a combined
positional and candidate association screen, by identify-
ing known WNT signaling genes, and showed that Dick-
kopf-4 was associated with schizophrenia [38]. There
have been no published investigations of the association
between WNT2 genetic polymorphisms and schizophre-
nia, despite its potentially important developmental roles
and its importance in genetics. In this study, therefore, we
investigated the association between WNT2 polymor-
phisms and schizophrenia in a Korean population.
Methods
Subjects
For this study, we evaluated 288 schizophrenic patients
(193 males, aged 42.98 ± 10.63 years [mean ± SD]; 95
females, aged 43.03 ± 10.65) and 305 controls with no
clinical evidence of any disorders (147 males, 39.92 ±
5.82; 158 females, 36.55 ± 6.77). The schizophrenic
patients met the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) [39] criteria
for schizophrenia. We reviewed each patient's medical
record and rated the schizophrenic patients using the
Brief Psychiatric Rating Scale (BPRS) [40], the Scale for
the Assessment of Negative Symptoms (SANS) [41], and
the operational criteria (OPCRIT) checklist [42].
T o evaluate patients for schizophrenia with poor con-
centration, we used the OPCRIT Checklist. Of the many
OPCRIT items, we selected only a few items, already
described in our previous study, for use [43]. We deter-
mined which patients to place in the poor concentration
subgroup according to patients' subjective complaints of
being unable to think clearly or make decisions (scoring:
1 for a duration of one week, 2 for two weeks, and 3 for
one month) [42]. Thus, we examined 167 schizophrenic
patients having poor concentration (116 males, 42.8 ±
10.0; 51 females, 41.9 ± 10.8) and 121 schizophrenic
patients who had no such complaints (77 males, 43.6 ±
11.2; 44 females, 44.8 ± 10.7). We also analyzed the asso-
ciations between the schizophrenic patients' SNPs and
their SANS scores (Table 1). The genotype frequencies of
rs6948009 was evaluated (A/A, n = 211; A/G, n = 71; G/
G, n = 3) for the analysis with SANS scores.
We recruited control subjects who had been found
mentally fit by a general health checkup program. All
studies were carried out according to the guidelines of the
Declaration of Helsinki [44]. We obtained written
informed consent from each subject. The study was
approved by the ethics review committee of the Medical
Research Institute, Kyung Hee University Medical Center,
Seoul, Republic of Korea.
SNP Genotyping
We selected 8 SNPs from WNT2 genes in chromosome
7q31.2 by downloading all the SNPs typed in the WNT2
genes from the HapMap database (http://www.hap-
map.org/;genome build 35) and dbSNP database version
129. From these, we selected tag SNPs using the Tagger
program's aggressive tagging option (Paul de Bakker,
http://www.broad.mit.edu/mpg/tagger/), so as to capture
SNPs with a minor allele frequency of < 5% (r2 > 0.8). This
gave 2 exonic SNPs (rs2024233 and rs1051751), 3 intronic
SNPs (rs733154, rs3779548, and rs17132543), and 3 regu-
latory SNPs (thought to be the promoter; the intervals are
2000 bp up- and downstream between the genes)
(rs6948009 [869 bp downstream from the last nucleotide
of the 3'-UTR], rs4730775 [164 bp downstream from the
last nucleotide of the 3'-UTR], and rs39315 [219 bp
upstream from the first nucleotide of the 5'-UTR]). In
addition, we chose these SNPs because they were previ-
ously evaluated for relation to schizophrenia risk or
s h o w e d  e v i d e n c e  o f  f u n c t i o n a l  s i g n i f i c a n c e .  F i g u r e  1
shows the locations of the selected SNPs.
Using a commercially available Qiagen DNA Extraction
kit (Qiagen, Tokyo, Japan), we extracted genomic DNA
from blood samples that had been placed in EDTA. We
amplified the genomic DNA using the primers shown in
Table 2 for each SNP, sequenced the PCR products using
an ABI Prism 377 automatic sequencer (PE Applied Bio-
systems, Foster City, California, USA), and analyzed the
sequence data using SeqManII software (DNASTAR Inc.,
Madison, Wisconsin, USA).
Statistical analysis
Using SNPstats, we assessed the Hardy-Weinberg equi-
librium (HWE) for both controls and schizophrenia
patients [45]. For the linkage disequilibrium (LD) block,
we used the Haploview version 3.32 [46]. We inferred the
haplotypes and their frequencies using the EM algorithm
[47]. We used the multiple logistic regression model to
calculate odds ratios (OR), 95% confidence intervals, and
corresponding  p  values (controlling age and gender as
covariables), to analyze the association between schizo-
phrenia and both SNPs and haplotypes. Furthermore, we
analyzed the association between the schizophrenia sub-
group and both SNPs and haplotypes, using SNPstats, the
HapAnalyzer version 1.0 [48], and Helixtree (GoldenKim et al. BMC Medical Genetics 2010, 11:78
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Table 1: WNT2 SNPs genotype and allele frequencies in schizophrenia patients and healthy controls
Schizophrenia Control
SNP Genotype Freq % Freq % Model OR (95% CI) P value
rs39315 A/A 90 0.31 79 0.26 co-dominant 1.21 (0.95-1.54) 0.12
5'-near gene A/G 137 0.48 150 0.49 dominant 1.38 (0.94-2.02) 0.1
G/G 61 0.21 76 0.25 recessive 1.20 (0.80-1.81) 0.38
rs17132543 A/A 97 0.34 98 0.32 co-dominant 1.14 (0.89-1.45) 0.3
Intron4 A/G 138 0.48 145 0.48 dominant 1.16 (0.80-1.68) 0.43
G/G 53 0.18 62 0.2 recessive 1.22 (0.79-1.89) 0.37
rs3779548 A/A 127 0.44 135 0.44 co-dominant 0.97 (0.74-1.25) 0.8
Intron4 A/G 128 0.44 136 0.45 dominant 0.99 (0.70-1.40) 0.96
G/G 33 0.11 34 0.11 recessive 0.88 (0.50-1.53) 0.65
rs733154 A/A 171 0.59 177 0.58 co-dominant 1.00 (0.74-1.33) 0.97
Intron4 A/G 103 0.36 109 0.36 dominant 1.02 (0.72-1.44) 0.93
G/G 14 0.05 19 0.06 recessive 0.89 (0.42-1.92) 0.78
rs2024233 A/A 87 0.3 84 0.28 co-dominant 1.11 (0.87-1.43) 0.41
3'-UTR A/G 148 0.51 157 0.51 dominant 1.15 (0.79-1.69) 0.46
G/G 53 0.18 64 0.21 recessive 1.14 (0.74-1.77) 0.54
rs4730775 G/G 176 0.61 184 0.6 co-dominant 0.89 (0.66-1.20) 0.45
3'-near gene G/A 94 0.33 112 0.37 dominant 1.02 (0.71-1.45) 0.93
A/A 17 0.06 9 0.03 recessive 0.35 (0.14-0.85) 0.017
Freq, frequency; OR, odds ratio; CI, confidence interval.
Helix Inc., MT, USA). We assessed the associations
between SNPs and SANS scores, using one-way ANOVA
to analyze the relationship between SANS scores and
genotype frequencies in the schizophrenia subgroup. We
calculated the power, given the sample size, using a
genetic power calculator http://pngu.mgh.harvard.edu/
~purcell/gpc[49], and, to reduce error , we adjusted the
effective sample size (calculated sample size × 100/95).
When we calculated the sample powers, we found our
case-control study was sufficiently powerful to determine
a  p o s i t i v e  a s s o c i a t i o n .  I n  t h i s  s t u d y ,  w e  f o u n d  s a m p l e
powers of 0.8046 (rs39315, effective sample size, number
of cases for 80% power = 284), 0.8493 (rs17132543, n =
252), 0.9338 (rs3779548, n = 188), 0.9677 (rs733154, n =
155), 0.9145 (rs2024233, n = 208), and 0.9689 (rs4730775,
n = 154) for detecting a two-fold increased risk, assuming
Figure 1 Gene map and single nucleotide polymorphisms (SNPs) in the WNT2 gene on chromosome 7q31.2. Exons are marked with boxes. 
The coding regions are black boxes. The first nucleotide is denoted as +1. The arrow indicates the location of each SNP.Kim et al. BMC Medical Genetics 2010, 11:78
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Table 2: Primer Sequences
SNP Sequence(5'-3') Product Size Temperature
rs39315 Forward CCTCCCTATGGGCTCTGTATT 450 60
Reverse CACGGGTGCATGAAATGATGG
rs17132543 Forward AGCCTCTAGAGAAGTCCTGAAG 373 60
Reverse CTCCCAACCACACTCACACACA
rs3779548 Forward GTGTGGCCTACTTTGCAGAAG 355 60
Reverse TTCTCCAGCACCTAGACTGTG
rs733154 Forward GGATCCTTGATCGAGCAGAGCCA 301 60
Reverse GACTGCAGCAGGAGAGACAGTTA
rs1051751 Forward TGGGCCCACAGAACGAGTATAAC 327 65
Reverse CCAGAGCTTCCAGGCAGTCCT
rs2024233 Forward GTAACAAGGTGGGGACGTGTGT 319 62
Reverse GAGATTCCATGGGTCACATGCA
rs4730775 Forward TGGGGATACAAGATTGGTGAAC 360 65
Reverse GATGGCAGAAGCCAACCACTA
rs6948009 Forward GGTCATTTAGACTGAGACTCG 461 60
Reverse CACCAATCCCTTCGCCTCTCT
an  α-level of 0.05. However, the sample powers in the
divided schizophrenia subgroup (with or without poor
concentration) were not sufficient (data not shown). We
applied the Bonferroni correction by multiplying P values
by the number of SNPs analyzed (n = 6).
Results
Of the eight SNPs we examined, all were polymorphic.
The genotype distributions of six SNPs (rs39315,
rs17132543, rs3779548, rs733154, rs2024233, and
rs4730775) were in HWE (P > 0.05). We did not estimate
one SNP (rs6948009) for the association analysis because
its genotype distribution was not in HWE (p  < 0.05).
Also, we excluded one SNP (rs1052751) from the analy-
sis, since it was not polymorphic. Of these SNPs, one SNP
(rs4730775) was weakly associated with schizophrenia.
Despite this association (p = 0.017 in the recessive
model), we could not prove the statistical significance of
analysis after the Bonferroni correction. Thus, these
results do not support a significant role for the WNT2
sequence variation in the etiology of schizophrenia.
Figure 2 Linkage disequilibrium (LD) blocks of the WNT2 gene. LD 
coefficient (|D'|) and LD blocks among WNT2 SNPs. Block 1 consists of 
rs4730775 and rs2024233. Block 2 comprises rs3779548 and 
rs17132543.Kim et al. BMC Medical Genetics 2010, 11:78
http://www.biomedcentral.com/1471-2350/11/78
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Table 3: WNT2 SNPs haplotype frequencies in schizophrenia patients and healthy controls.
Haplotype Schizophrenia Control
(Block 1) Type Freq % Freq Freq % Freq Models OR(95% CI) P value
HH 51 0.19 66 0.21 co-dominant 0.92(0.73-1.16) 0.4778
HAP1 GG H- 142 0.52 0.44 163 0.51 0.46 dominant 0.91(0.64-1.31) 0.6236
-- 82 0.3 89 0.28 recessive 0.87(0.58-1.31) 0.5004
HH 31 0.11 37 0.12 co-dominant 1.04(0.82-1.32) 0.7506
HAP2 GA H- 121 0.44 0.33 132 0.42 0.32 dominant 1.09(0.79-1.51) 0.604
-- 123 0.45 149 0.47 recessive 0.96(0.58-1.60) 0.8901
HH 15 0.05 11 0.03 co-dominant 1.07(0.81-1.42) 0.6325
HAP3 AA H- 93 0.34 0.22 113 0.36 0.21 dominant 1.01(0.73-1.41) 0.9446
-- 167 0.61 194 0.61 recessive 1.61(0.73-3.57) 0.2405
Haplotype Schizophrenia Control
(Block 2) Type Freq % Freq Freq % Freq Models OR(95% CI) P value
HH 50 0.18 65 0.2 co-dominant 0.90(0.72-1.14) 0.3894
HAP1 AG H- 130 0.47 0.42 152 0.48 0.44 dominant 0.88(0.63-1.24) 0.4723
-- 95 0.35 101 0.32 recessive 0.86(0.57-1.30) 0.4881
HH 31 0.11 35 0.11 co-dominant 1.01(0.80-1.29) 0.912
HAP2 GA H- 123 0.45 0.34 142 0.45 0.33 dominant 1.01(0.73-1.40) 0.9338
-- 121 0.44 141 0.44 recessive 1.03(0.62-1.72) 0.9181
HH 15 0.05 14 0.04 co-dominant 1.12(0.86-1.48) 0.4011
HAP3 AA H- 104 0.38 0.24 114 0.36 0.22 dominant 1.13(0.82-1.57) 0.4568
-- 156 0.57 190 0.6 recessive 1.25(0.59-2.64) 0.5543
Freq, frequency; OR, odds ratio; CI, confidence intervals.
To further analyze the haplotype structure in our sam-
ples, we characterized the two LD blocks between the six
WNT2  SNPs (including the 5'UTR and 3'UTR) in the
control subjects, using the pairwise D'values (Figure 2).
Per the criteria used by Gabriel et al. [50], the LD data
revealed two haplotype blocks across WNT2. The D' val-
ues from rs4730775 to rs32024233 and from rs37795488
to rs17132543 ranged between 0.95 and 0.99, indicating
strong LD between each pair of markers (Figure 2). We
performed a haplotype-based association analysis
between the schizophrenic and control groups for differ-
ent combinations of SNPs within WNT2, revealing two
LD blocks (block 1, rs4730775 and rs32024233; block 2,
rs37795488 and rs17132543). However, we did not detect
significant associations between the haplotypes in block 1
or 2 and schizophrenia (all p-values of the analysis > 0.05;
Table 3). We then assessed the gene and haplotype associ-
ations with these SNPs in the poor-concentration schizo-
phrenia subgroup (determined using the OPCRIT
Checklist). In this subgroup, the genotype distributions of
the seven SNPs considered were in HWE (p > 0.05). We
then analyzed the genetic associations of these SNPs
within the subgroup. The SNPs of the WNT2 gene were
not associated with poor concentration, a clinical symp-
tom of schizophrenia (Table 4). In addition, we assessed
the associations between SNPs and SANS scores. No sta-
tistically significant differences appeared in the total
SANS scores among the seven SNPs (Table 5). To com-
pare our genotypic results with different ethnic popula-
t i o n s ,  w e  s e a r c h e d  t h e  h u m a n  S N P  d a t a b a s e  ( h t t p : / /Kim et al. BMC Medical Genetics 2010, 11:78
http://www.biomedcentral.com/1471-2350/11/78
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Table 4: WNT2 genotype frequencies in Korean schizophrenia patients with poor concentration
NPC PC
SNP Genotype Freq % Freq % Model OR (95% CI) P value
rs39315 A/A 40 33.1 50 29.9 co-dominant 0.97 (0.70-1.34) 0.85
5'-near gene A/G 52 43.0 85 50.9 dominant 1.16 (0.70-1.92) 0.57
G/G 29 24.0 32 19.2 recessive 0.75 (0.43-1.33) 0.33
rs17132543 A/A 40 33.1 57 34.1 co-dominant 0.99 (0.71-1.38) 0.95
Intron4 A/G 59 48.8 79 47.3 dominant 0.96 (0.59-1.58) 0.88
G/G 22 18.2 31 18.6 recessive 1.02 (0.56-1.87) 0.95
rs3779548 A/A 50 41.3 77 46.1 co-dominant 0.90 (0.63-1.27) 0.54
Intron4 A/G 57 47.1 71 42.5 dominant 0.82 (0.51-1.32) 0.42
G/G 14 11.6 19 11.4 recessive 0.99 (0.47-2.06) 0.97
rs733154 A/A 67 55.4 104 62.3 co-dominant 0.84 (0.56-1.27) 0.41
Intron4 A/G 50 41.3 53 31.7 dominant 0.71 (0.44-1.15) 0.17
G/G 4 3.3 10 6.0 recessive 1.77 (0.53-5.89) 0.34
rs2024233 A/A 38 31.4 49 29.3 co-dominant 1.11 (0.79-1.57) 0.53
3'-UTR A/G 63 52.1 85 50.9 dominant 1.10 (0.66-1.83) 0.72
G/G 20 16.5 33 19.8 recessive 1.23 (0.67-2.28) 0.50
rs4730775 G/G 70 57.9 106 63.9 co-dominant 0.87 (0.59-1.28) 0.48
3'-UTR G/A 45 37.2 49 29.5 dominant 0.76 (0.47-1.24) 0.27
A/A 6 5.0 11 6.6 recessive 1.29 (0.46-3.62) 0.62
rs6948009 G/G 87 73.1 124 74.7 co-dominant 0.80 (0.48-1.33) 0.39
3'-near gene G/A 29 24.4 42 25.3 dominant 0.89 (0.52-1.53) 0.67
A/A 3 2.5 0 0 recessive 0.00 (0.00-NA) 0.02
Freq, frequency; NPC, nonpoor concentration; PC, poor concentration; OR, odds ratio; CI, confidence interval; N/A, not applicable.
www.ncbi.nlm.nih.gov/SNP dbSNP Build 130). This data-
base presents genotype frequencies for the SNPs ana-
lyzed in this study (Table 6). The control group's
genotype distributions of the SNPs we analyzed are simi-
lar to those of Asian populations, especially the Japanese
population (Table 6).
Discussion
The  WNT2  gene and its chromosomal location have
received attention as a candidate gene with regard to
autism. Given the similarities between autistic disorders
and schizophrenia (as a neurodevelopmental disorder),
we investigated whether WNT2 gene variations act as risk
factors for schizophrenia in a Korean sample. The results
suggest that WNT2 may not be involved in the pathogen-
esis of schizophrenia. Of all the SNPs and haplotypes ana-
lyzed, only one SNP (rs4730775) showed a weak
association with the disorder. However, the significance
disappeared after the Bonferroni correction for multiple
testing (p = 0.102, Table 1). In addition, we investigated
the LD between the WNT2 SNPs and performed a haplo-
type analysis between the schizophrenia and control sub-
jects. We could not find any association between WNT2
and schizophrenia, indicating that there is no genetic
association between WNT2 and schizophrenia.
To further analyze the association test between clinical
symptoms and SNP genotypes, we evaluated other symp-
toms, from the OPCRIT checklist and the total SANSKim et al. BMC Medical Genetics 2010, 11:78
http://www.biomedcentral.com/1471-2350/11/78
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scores. However, we found no statistically significant
association between any symptom in OPCRIT (Table 4)
and total SANS score (Table 5). We compared our geno-
type frequencies with the human SNP database http://
www.ncbi.nlm.nih.gov/sites/entrez?db=snp, to show eth-
nic similarities and differences. The genotype frequencies
of our study sample resemble those of the Japanese and
Chinese Hapmap populations (Table 6). Further studies
are necessary to elucidate (i) whether another case-con-
trol study is appropriate and (ii) whether promoter SNPs
can affect the expression of WNT2. To confirm or refute
the lack of association between the WNT2  gene and
schizophrenia, replication studies with adequate sample
sizes, or studies with additional SNPs not analyzed in the
present study, may be required.
This report has several limitations. First, the sample
size may not have been sufficient to detect associations of
smaller effects on schizophrenia. We estimated that this
sample had more than 0.8 powers to detect association,
with the gene exerting a genotypic relative risk of approx-
imately 2. However, schizophrenia appears to be a very
genetically complex disease, and the WNT2 gene risks
may be smaller than 2. Second, when we designed the
experiment, the versions of the HapMap database and
dbSNP database were slightly different compared to their
present forms, and, as a result, our selection of SNPs pro-
vided incomplete coverage of currently-known common
variations in the WNT2 gene. Furthermore, the present
databases showed different locations for some SNP from
Table 5: Comparison of SANS scores between schizophrenic patient groups with different genotypes of WNT2.
SANS
SNP Genotype n Mean S.E. P value
rs39315 A/A 90 66.78 2.627 0.388
5'-near gene A/G 137 63.76 2.239 0.866
G/G 61 64.41 2.831 0.55
rs17132543 A/A 97 63.99 2.46 0.458
Intron4 A/G 138 66.51 2.256 0.278
G/G 53 62.06 3.016 0.63
rs3779548 A/A 127 66.42 2.139 0.689
Intron4 A/G 128 65.17 2.257 0.124
G/G 33 57.48 4.394 0.062
rs733154 A/A 171 66.11 1.946 0.371
Intron4 A/G 103 63.32 2.375 0.684
G/G 14 60.5 6.791 0.429
rs2024233 A/A 87 60.26 2.717 0.031
3'-UTR A/G 148 67.59 2.034 0.461
G/G 53 64.68 3.319 0.311
rs4730775 G/G 176 65.82 1.85 0.267
3'-UTR G/A 94 64.23 2.63 0.619
A/A 17 58.82 6.56 0.427
rs6948009 A/A 211 65.02 1.81 0.981
3'-near gene A/G 71 64.94 2.5 0.307
G/G 3 52.33 3.38 0.406
SANS, Scale for the Assessment of Negative Symptoms; S.E., Standard Error; SNP, single nucleotide polymorphism.Kim et al. BMC Medical Genetics 2010, 11:78
http://www.biomedcentral.com/1471-2350/11/78
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Table 6: WNT2 SNPs genotype frequencies in each population
SNP Genotype Schizophrenia Control Europe China Japan Sub-Saharan 
African
rs39315 A/A 0.31 0.26 0.36 0.29 0.46 0.22
5'-near gene A/G 0.48 0.49 0.41 0.62 0.43 0.44
G/G 0.21 0.25 0.22 0.09 0.11 0.34
P value 0.285 0.010 0.003 0.373
rs17132543 A/A 0.34 0.32 0.78 0.24 0.44 0.97
Iintron4 A/G 0.48 0.48 0.22 0.58 0.47 0.03
G/G 0.18 0.20 0.00 0.18 0.09 0.00
P value 0.000 0.334 0.048 0.000
rs3779548 A/A 0.44 0.44 0.30 0.69 0.36 0.17
Intron4 A/G 0.44 0.45 0.47 0.22 0.44 0.65
G/G 0.11 0.11 0.23 0.09 0.20 0.18
P value 0.031 0.001 0.180 0.000
rs733154 A/A 0.59 0.58 0.85 0.62 0.31
Intron4 A/G 0.36 0.36 No data 0.13 0.31 0.37
G/G 0.05 0.06 0.03 0.08 0.33
P value N/A 0.000 0.675 0.000
rs1051751 G/G 1.00 1.00 1.00 1.00 0.98 1.00
Exon 5 G/T 0.00 0.00 0.00 0.00 0.02 0.00
Cys294Phe T/T 0.00 0.00 0.00 0.00 0.00 0.00
P value N/A N/A N/A N/A
rs2024233 A/A 0.30 0.28 0.50 0.29 0.34 0.54
3'-UTR A/G 0.51 0.51 0.40 0.44 0.50 0.41
G/G 0.18 0.21 0.10 0.27 0.16 0.05
P value 0.003 0.526 0.531 0.000
rs4730775 G/G 0.61 0.60 0.37 0.71 0.62 0.46
3'-near gene G/A 0.33 0.37 0.36 0.27 0.29 0.45
A/A 0.06 0.03 0.27 0.02 0.09 0.09
P value 0.000 0.261 0.135 0.060
rs6948009 A/A 0.74 0.53 0.95 0.93
3'-near gene A/G 0.25 0.45 No data 0.05 0.05 No data
G/G 0.01 0.02 0.00 0.02
P value N/A 0.000 0.000 N/A
From database http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp. We estimated all p-values via comparisons between the control group of our 
sample and each population. N/A, not applicable.Kim et al. BMC Medical Genetics 2010, 11:78
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previous databases. Consequently, we may have missed
some of the relevant associations of WNT2  genes.
Conclusions
We investigated possible associations between WNT2
gene SNPs and schizophrenia, and the results were nega-
tive. For that reason, it appears the SNPs of WNT2 may
not influence the development of schizophrenia in the
Korean population, but, still, additional genetic studies
will help develop understanding of the precise mecha-
nisms underlying pathogenesis in schizophrenic patients.
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